There are good things ahead for biotech…

Porter took the stage this morning to give a rundown of what’s happening with medical research that will lead to discoveries that will lead to life-changing opportunities in wealth creation. Running through his newly created barbell portfolio for Porter & Co. Biotechnology, Porter pulled out one promising stock in particular to recommend. “It’s a speculative buy,” he said, “but their pipeline is promising and four of the five top biotech investors have money in this business.”

He left the audience with two key takeaways: 1) there will be an immune-fighting tool to cure many forms of cancer within 10 years, and 2) if you find biotech too speculative or confusing, at the very least put some money into a biotech ETF.

Porter & Co. analyst Jared Simons shared with the audience an exciting software/gaming stock that has grown one portion of its business from zero to $1 billion in revenue in just 18 months – and growth just accelerated last quarter. The stock went from over $200 per share to $17 in 2021, but has since rebuilt its model and its reputation with the key developer stakeholders. Now infusing innovation with AI and adding robots into the mix, Jared sees 50% share-price growth as a conservative estimate over the next two years. The big catalyst to share-price movements come in early November when the company releases Q3 earnings.

Distressed Investing analyst Marty Fridson emerged after the mid-morning break to tout the performance of his distressed-bond and distressed-equity recommendations. His closed bond positions returned 24%, while the combined stock-bond selections soared 103% from the time of recommendation to closing out the trade.

What’s new since the last conference is the addition of the Income Streams portfolio as part of Distressed Investing… as a way to generate various streams of income in addition to the value gained from an investment’s price appreciation.

Marty explained that you can earn consistently decent overall returns from an income investment just as you can from simply owning shares of a company – but with income investments, most of the returns come from dividends, interest payments, or other cash disbursements and not from the appreciation of the share price.

He also discussed the advantages of such an investment strategy – such as providing living expenses and reducing volatility – and then shared the results, up 8.25% over the past 12 months, outperforming the benchmarks